Aktuella utlysningar, vecka 42, 2021
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Grants for research on prostate cancer and breast cancer - Percy Falks Stiftelse
Promote research and education or study activities in Sweden concerning prostate cancer and breast cancer. The total budget is SEK 2 million.
Closing date: 1 November 2021
Research grants - Prostatacancerförbundet
Support research projects that strengthen and develop the state of knowledge in the field of prostate cancer, including psychosocial and medical aspects of the disease.
Closing date: 15 November 2021
Excellence emerging investigator grant within endocrinology and metabolism, Nordic region - Novo Nordisk Foundation
With this call the Novo Nordisk Foundation seeks to support and strengthen the development of young and promising research leaders, and to promote Nordic research at a high international level. The call is targeted starting group leaders with ambitious projects within endocrinology and metabolism that aim to understand the human organism and the mechanisms underlying health and disease at a basic and clinical level. Four grants are available for funding and NNF aims at awarding at least one of these grants to an active clinician researcher.
Closing date: 13 January 2022
Ascending investigator grant within endocrinology and metabolism, Nordic region - Novo Nordisk Foundation
The purpose of this call is to stimulate the continued development of excellent research leaders, and promote Nordic research at a high international level. The Novo Nordisk Foundation (NNF) seeks to support the consolidation of accomplished associate professors with ambitious projects within endocrinology and metabolism to understand the human organism and the mechanisms underlying health and disease at a basic and clinical level. Three grants are available for funding.
Closing date: 13 January 2022
Distinguished investigator grant within endocrinology and metabolism, Nordic region - Novo Nordisk Foundation
To promote Nordic research at the highest international level the Novo Nordisk Foundation (NNF) seeks to support outstanding professors with ambitious projects within endocrinology and metabolism to understand the human organism and the mechanisms underlying health and disease at a basic and clinical level. NNF will award up to two grants.
Closing date: 13 January 2022
Forskningsanslag från Clas Groschinskys minnesfond öppnar den 20 november 2021
Anslagen riktar sig till forskare inom:
- social- och beteendevetenskap
- social verksamhet
All information, ansökningsblanketter och villkor för anslag/stipendier finns från och med 20 november 2021 på stiftelsens hemsida: www.groschinsky.org.
Ansökningshandlingar skall vara stiftelsen tillhanda senast 31 januari 2022.
Seed funding available for research collaboration with University College London (UCL)
The UCL Cities partnerships Programme Funds 2021-22 announces that funding is available for joint projects between UCL academics and the Stockholm Trio (Karolinska Institutet, KTH Royal Institute of Technology and Stockholm University).
These funds will be jointly contributed by UCL and the Stockholm Trio.
The deadline for UCL applications is 23:59 UK time on 31 October 2021. KI researchers that partner with UCL in an application are eligible to apply for co-funding from KI to fund their contribution to the project, subject to internal prioritisation.
Project must be undertaken between December 2021 and 31 July 2022.
If you have any questions about the application process for KI seed funding please contact Lotta Lundqvist, international relations office at firstname.lastname@example.org
Postdoctoral research fellowship exchange programme, European Committee for Treatment and Research in Multiple Sclerosis, CH
The European Committee for Treatment and Research in Multiple Sclerosis invites applications for its postdoctoral research fellowship exchange programme. This supports young neuroscientists to facilitate their conduct of and training in basic, clinical or applied research related to multiple sclerosis. This aims to maximise exchange of information and to help grow a pool of research scientists focused on problems in multiple sclerosis. The fellowship is conducted at a European research laboratory or clinic.
Budget: €55,000 per year for to two years.
Deadline: 1 December 2021
Research grants, Cure Parkinson’s Trust, GB
The Cure Parkinson’s Trust invites applications for its research grants. These support laboratory or clinical research projects that have the potential to advance knowledge that might lead to a cure for Parkinson’s disease. Applications must be for research that slows, stops or reverses underlying disease progression. Priority is given to research which has potential to translate into the clinic within five years.
Budget: Pre-clinical grants up to £250,000, sub-studies of clinical trials and clinical trials can be funded.
Deadline: 3 December 2021
Targeted call – understanding the role of non-canonical functions of PTEN in PHTS PTEN Research, GB
Grants awarded through this Targeted Call are intended primarily to advance the understanding of the non-canonical functions of PTEN (i.e., those that are independent of the regulation of PI3K signalling) and specifically address their contribution to the pathobiology of PTEN hamartoma tumour syndrome (PHTS). Investigators with expertise in PTEN, PHTS and/or non-canonical signalling pathways regulated by PTEN are encouraged to apply.
Eligibility: Principal Investigators who hold a MD or PhD and have an established research programme or faculty position in a recognised academic or clinical research institution.
Budget: Funding requests of up to £200,000 GBP (or equivalent in local currency) for two to three years will be considered.
Deadline: 13 December 2021 (Letter of Intent), 7 January 2022 (Full application)
Research grants, European Hematology Association, EUR
The European Hematology Association invites applications for its research grants. These enable early-career researchers in the field of haematology to advance their career towards becoming the leader of a research group. Research must be basic or translational lab-based research. The following awards are available:
Junior Research Grant: €50.000, - per year, for 3 years
For researchers doing basic research within 4 years of their PhD graduation. The month of graduation must be less than 4 years before the closing date of the application. Exceptions must be justified.
Advanced Research Grant: €80.000, - per year, for 2 years
For researchers doing basic research 4-8 years after their PhD graduation. This is the time interval between the month of graduation and the closing date of the application. Exceptions must be justified.
Physician Scientist Research Grant: €80.000, - per year, for 2 years
For physician scientists who are involved in patient care and:
- Are MD or equivalent
- Are within 4 years after PhD graduation OR MD graduation OR hematology training (or equivalent), whatever comes last at the closing date of the application. Exceptions must be justified.
- Have a proven track record in research by publications
- Must have at least 50% protected time for performing the research project, to be justified in the letter of support by the Head of Department where the research will be performed.
- It is highly preferred that the topic of research is related to the specialty in the clinic. (e.g. LAB: developing a mouse model in MPN, CLINIC: treating MPN)
Deadline: 16 December 2021, 12:00 (CET)
Federal Funding agencies
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional), NIH
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).
Deadline: June 07, 2022; October 07, 2022; June 07, 2023; October 09, 2023; June 07, 2024; October 08, 2024. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-21-341
Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01; R21 Clinical Trial Not Allowed), NIH
The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.
Deadline: NIH standard due dates until January 08, 2025. All applications are due by 5:00 PM local time of applicant organization.
Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer’s Disease and Related Dementias (R01 Clinical Trial Not Allowed), NIH
This Funding Opportunity Announcement (FOA) supports mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). It is expected that these studies will address the clinical relevance of these exposures on disease initiation, progression, or modification. Anticipated outcomes include an improved understanding of neurological mechanisms of chemical toxicities related to AD/ADRD, more evidence-based potential biomarkers of exposure and toxicity for those most at risk, as well as more data to support causality and potential approaches for mitigation. The scope of research includes mechanistic studies on the modification of known AD/ADRD targets by neurotoxins of concern, and conversely, whether known targets for these neurotoxins play a role in etiologies of AD/ADRD. The development and validation of neuropathological, neurophysiological and neurobehavioral animal models that simulate potential toxin exposures in humans is another example of supported studies. Preclinical studies of interactions of environmental toxicant with AD/ADRD in pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA. Interdisciplinary collaboration is required to address the various fields of study related to this research, e.g., neuroscience, aging, and environmental health sciences.
Deadline: March 11, 2022. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-22-048
Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed), NIH
The purpose of this Funding Opportunity Announcement (FOA) is to support discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation for broad protection against GAS infections.
Deadline: February 18, 2022 .All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-AI-21-070
Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required; R01 Clinical Trials Not Allowed; R01 Clinical Trial Required), NIH
This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Mechanistic studies are defined as studies with the objective to understand the mechanism(s) of action of an intervention, a biological or behavioral process, or the pathophysiology of a disease/condition. See NOT-AT-20-001 and NOT-MH-19-006 for examples of clinical trials that are/are not considered mechanistic studies. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Researchers proposing basic science experimental studies involving human participants should consider this FOA’s companion for basic experimental studies with humans, PAR-21-349, “Research on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required).” Applications proposing studies that include, but are not limited to, model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).
Deadline: June 21, 2022; June 21, 2023; June 21, 2024. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-21-349 (R01 Basic Experimental Studies with Humans Required); PAR-21-350 (R01 Clinical Trials Not Allowed), PAR-21-352 (R01 Clinical Trial Required).
Pilot study awards & Scientific scholar awards, Rivkin Center for Ovarian Cancer Research, US
Pilot study awards
The Rivkin Center for Ovarian Cancer Research invites applications for its pilot study awards. These support investigator-initiated projects in all areas of ovarian cancer research. Projects designed to analyse data from already funded clinical trials will also be considered.
Awards are worth USD 75,000 each over one year, with an additional USD 25,000 potentially being available for a limited number of projects for an additional year.
Scientific scholar awards
The Rivkin Center for Ovarian Cancer Research invites applications for its scientific scholar awards. These support laboratory and clinical scientists in pursuing careers as independent investigators in ovarian cancer research. The goal is to attract junior investigators as well as established investigators into ovarian cancer research and to develop their potential as leaders.
Applicants must have an MD, PhD or equivalent degree with career goals focused on ovarian cancer. Clinicians must have completed their residency. Candidates should be at the postdoctoral, fellow, instructor, research assistant or assistant professor level with no more than three to four years in any of these positions. Established scientists without prior focus in ovarian cancer but looking to focus on this disease area are also encouraged to apply.
Awards are worth up to USD 120,000 each over two years.
Deadline: December 1, 2021 at 5pm EST.
Clinic and laboratory integration programme grants, Cancer Research Institute, US
The Cancer Research Institute invites letters of intent for its clinic and laboratory integration programme grants. These support scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. Grants support preclinical and translational research that can be directly applied to optimising cancer immunotherapy in the clinic.
Candidates must be qualified scientists who hold a faculty appointment as a tenure-track assistant professor, or higher rank, at the time of the award activation.
Grants are worth up to USD 100,000 each per year for two years. Funding covers salary, technical assistance, supplies, capital equipment or scientific travel costs. Indirect costs are not covered.
Deadline: December 1, 2021 (LOI); March 1, 2022 (Full Proposal).
Small research grants, Spencer Foundation, US
The Spencer Foundation invites proposals for its small research grants. These support smaller scale or pilot projects that will contribute to the improvement of education, broadly conceived. Work that fosters creative and open-minded scholarship, engages in deep inquiry and examines robust questions related to education is encouraged.
Grants are worth up to USD 50,000 each for between one and five years.
Deadline: December 1, 2021 12:00PM (Noon) Central Time.
Research centres of excellence, Parkinson’s Foundation, US
The Parkinson’s Foundation, under its institutional movement disorder fellowship programme, invites applications for its research centres of excellence funding opportunity. This supports innovative team science at institutions working on a thematic area of Parkinson’s disease. Proposals must tackle critical issues or problems that are impeding progress in the field of Parkinson’s disease research. Preference will be given to applications which demonstrate cross-departmental or cross-institutional collaboration.
Institutions that have or can recruit a team of scientists working in the field of Parkinson’s disease may apply. Each team should have at least three PIs at the faculty-level and may also include postdoctoral fellows, graduate students and research technicians.
Grants are worth USD 500,000 each per year over four years. Of this, USD 50,000 per year must be reserved for pilot work and new collaborations.
Deadline: LOI Due: December 1, 2021; Application Due: March 21, 2022; Award Notification: June 2022; Award Begins: July 1, 2022.
Research grants, Cystic Fibrosis Foundation, US
The Cystic Fibrosis Foundation invites applications for its research grants. These encourage the development of new information that contributes to the understanding of the basic aetiology and pathogenesis of cystic fibrosis. Studies must focus on basic science research.
Awards are worth up to USD 125,000 per year for up to two years, with the possibility of renewal.
Deadline: December 7, 2021.